The “Paleontology” of Antibiotics and Antibiotic Resistance

While preparing for a recent talk, I did a brief search for articles on bacterial antibiotic resistance prior to the development of modern day antibiotics. We understand that bacteria predate humans by a few billion years, and many of today’s antibiotics are derived from molecules made by fungi (i.e. penicillin and cephalosporins) and soil bacteria […]

WHO Report on Antibiotic Pipeline and Online Consultation on Monitoring the Global Action Plan

The World Health Organization (WHO) has been visibly busy this month in the area of antimicrobial resistance (AMR). The agency released a report on the global pipeline of new antibiotics (including anti-tuberculosis drugs) on 19th September. It can be downloaded here. There is also a new infographic on what WHO considers priority pathogens in addition […]


The annual European Congress of Clinical Microbiology and Infectious Diseases is going on now at the Amsterdam RAI Exhibition and Convention Centre, and will end on 12th April. This meeting has grown from strength to strength, and now has more than 11,000 attendees each year.       Attending the session on individualised management of invasive […]

The Antibiotic Pipeline Dilemma

A short summary of the current dilemma with antibiotic development. Others, including the World Health Organization and Infectious Diseases Society of America, have expressed this issue more elegantly and in greater detail (click on the links to check out), but it bears repeating: Drug discovery is tough. Discovering or creating a new (i.e. novel class of antibiotics) antibiotic […]

Teixobactin and iChip

I have finally had the chance to read the Nature article (behind a pay wall) that has been making waves in the recent news, including the Guardian, Forbes and Bloomberg among others. The authors, who are from academic institutions in the USA (Boston) and Germany (Bonn), as well as a drug discovery company from the UK (Selcia, Ongar, […]